南京蓝盾生物科技

Nanjing Landun Biotechnology is a clinical-stage biotechnology company based in Nanjing, China, specializing in the development of innovative cell therapies for oncology. The company focuses on chimeric antigen receptor T-cell (CAR-T) therapies, TCR-T, and NK cell-based treatments targeting both hematological malignancies and solid tumors. Their research pipeline includes candidates targeting CD19 and BCMA for hematological malignancies, as well as GPC3 and Mesothelin for solid tumors. Landun Biotech utilizes proprietary technology platforms to optimize cell production and enhance the therapeutic potential of its products. The company is committed to advancing precision oncology through innovative cell engineering and clinical translation.